6cyg: Difference between revisions
New page: '''Unreleased structure''' The entry 6cyg is ON HOLD Authors: Description: Category: Unreleased Structures |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
The | ==Hsp90-alpha N-domain bound to NEOCA== | ||
<StructureSection load='6cyg' size='340' side='right'caption='[[6cyg]], [[Resolution|resolution]] 1.50Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6cyg]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6CYG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6CYG FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.503922Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=N5O:5-N-(2-HYDROXYL)ETHYL+CARBOXYAMIDO+ADENOSINE'>N5O</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6cyg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6cyg OCA], [https://pdbe.org/6cyg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6cyg RCSB], [https://www.ebi.ac.uk/pdbsum/6cyg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6cyg ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/HS90A_HUMAN HS90A_HUMAN] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.<ref>PMID:15937123</ref> <ref>PMID:11274138</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The hsp90 chaperones govern the function of essential client proteins critical to normal cell function as well as cancer initiation and progression. Hsp90 activity is driven by ATP, which binds to the N-terminal domain (NTD) and induces large conformational changes that are required for client maturation. Inhibitors targeting the ATP binding pocket of the NTD have anticancer effects, but most bind with similar affinity to cytosolic Hsp90alpha and beta, endoplasmic reticulum Grp94, and mitochondrial Trap1, the four cellular hsp90 paralogs. Paralog-specific inhibitors may lead to drugs with fewer side effects. The ATP binding pockets of the four paralogs are flanked by three side pockets, termed Sites 1, 2, and 3, which differ between the paralogs in their accessibility to inhibitors. Previous insights into the principles governing access to Sites 1 and 2 have resulted in the development of paralog-selective inhibitors targeting these sites, but the rules for selective targeting of Site 3 are less clear. Previous work identified 5'N-ethylcarboxamido adenosine (NECA) as a Grp94-selective ligand. Here, we use NECA and its derivatives to probe the properties of Site 3. We found that derivatives that lengthen the 5' moiety of NECA improve selectivity for Grp94 over Hsp90alpha. Crystal structures reveal that the derivatives extend further into Site 3 of Grp94 compared to their parent compound and that selectivity is due to paralog-specific differences in ligand pose and ligand-induced conformational strain in the protein. These studies provide a structural basis for Grp94-selective inhibition using Site 3. | |||
NECA derivatives exploit the paralog-specific properties of the Site 3 side pocket of Grp94, the ER Hsp90.,Huck JD, Que NLS, Immormino RM, Shrestha L, Taldone T, Chiosis G, Gewirth DT J Biol Chem. 2019 Sep 9. pii: RA119.009960. doi: 10.1074/jbc.RA119.009960. PMID:31501246<ref>PMID:31501246</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6cyg" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Heat Shock Protein structures|Heat Shock Protein structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Campomizzi C]] | |||
[[Category: Gewirth DT]] | |||
[[Category: Huck JD]] | |||
Latest revision as of 18:13, 4 October 2023
Hsp90-alpha N-domain bound to NEOCAHsp90-alpha N-domain bound to NEOCA
Structural highlights
FunctionHS90A_HUMAN Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.[1] [2] Publication Abstract from PubMedThe hsp90 chaperones govern the function of essential client proteins critical to normal cell function as well as cancer initiation and progression. Hsp90 activity is driven by ATP, which binds to the N-terminal domain (NTD) and induces large conformational changes that are required for client maturation. Inhibitors targeting the ATP binding pocket of the NTD have anticancer effects, but most bind with similar affinity to cytosolic Hsp90alpha and beta, endoplasmic reticulum Grp94, and mitochondrial Trap1, the four cellular hsp90 paralogs. Paralog-specific inhibitors may lead to drugs with fewer side effects. The ATP binding pockets of the four paralogs are flanked by three side pockets, termed Sites 1, 2, and 3, which differ between the paralogs in their accessibility to inhibitors. Previous insights into the principles governing access to Sites 1 and 2 have resulted in the development of paralog-selective inhibitors targeting these sites, but the rules for selective targeting of Site 3 are less clear. Previous work identified 5'N-ethylcarboxamido adenosine (NECA) as a Grp94-selective ligand. Here, we use NECA and its derivatives to probe the properties of Site 3. We found that derivatives that lengthen the 5' moiety of NECA improve selectivity for Grp94 over Hsp90alpha. Crystal structures reveal that the derivatives extend further into Site 3 of Grp94 compared to their parent compound and that selectivity is due to paralog-specific differences in ligand pose and ligand-induced conformational strain in the protein. These studies provide a structural basis for Grp94-selective inhibition using Site 3. NECA derivatives exploit the paralog-specific properties of the Site 3 side pocket of Grp94, the ER Hsp90.,Huck JD, Que NLS, Immormino RM, Shrestha L, Taldone T, Chiosis G, Gewirth DT J Biol Chem. 2019 Sep 9. pii: RA119.009960. doi: 10.1074/jbc.RA119.009960. PMID:31501246[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||